secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-262562
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0
----------------------------------------------------------------------

- Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.
- Acquired VISTA-inhibiting mAb TBS-2025 via Kineta merger (June 2025); planning Phase 2 in mutNPM1 AML.
- Deferred development of IFx-3.0 mRNA candidate pending IFx-2.0 Phase 3 data; resources shifted to TBS-2025.
- Filed unaudited pro forma financials reflecting Kintara (Oct 2024) and Kineta (June 2025) mergers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/0001193125-25-262562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000119312525262562/d73851d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-262562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer